CompletedPhase 1NCT02680808

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Studying Aspergillosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
F2G Biotech GmbH
Principal Investigator
FRANS VANDENBERG
Hammersmith Medicines Research
Intervention
Midazolam with F901318(drug)
Enrollment
20 enrolled
Eligibility
18-45 years · MALE
Timeline
2016 – 2016

Study locations (1)

Collaborators

Hammersmith Medicines Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02680808 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials